LI Jinjun
Professor
Email: [email protected]
Tel：021-64432140
Research field：
1. Clinical Basic Research on Targeted Therapy of Liver Cancer Stem Cells
2. Study on the molecular mechanism of drug resistance in liver cancer
3. Study on the molecular mechanism of tumor metastasis
Biography
In 1997, Professor Li received his PhD degree from National Yamaguchi University, Japan. Dr. Li is currently the head of the research team of the State Key Laboratory of Cancer Genes and Related Genes, Shanghai Cancer Institute. Dr. Li has been focusing on cancer stem cells (CSCs), signaling transduction, mechanism of tumor metastasis and drug resistance, as well as pre-clinical researches for hepatocellular carcinoma. He has undertaken 6 National Natural Science Foundation of China (NSFC) General Projects, "Eleventh Five-Year Plan" and "12th Five-Year Plan" National Science and Technology Major Special Projects of each category one projects as well as one "13th Five-Year Plan" National Science and Technology Major Special sub-Project, participated in one of “973” project, currently undertaking 2 general projects of NSFC. From 2011 to 2020, Dr. Li had published 74 SCI papers (including 35 papers as corresponding author, including 2 Hepatology, 1 Biomaterials, 3 Cancer Res, 1 Oncogene, 1 J Exp Clin Cancer Res, 1 Mol Cancer Therap journal papers), and participated in the editing of 3 books. It has declared 14 national invention patents (11 of which have been authorized). In 2006, he enjoyed the special allowance of the State Council. In 2009, he was selected as the municipal outstanding academic leader training program (Class A), the local training program for leading talents in Shanghai, and the national talent training program for the "New Century Talent Project". Dr. Li is Member of the 12th and 13th Shanghai Committee of the Chinese People's Political Consultative Conference (CPPCC).
Publications
Zhenyu Wang, Xiaoxia Chen, Lianer Zhou, Xinge Zhao, Chao Ge, Fangyu Zhao, Haiyang Xie, Taoyang Chen, Hua Tian, Hong Li and Jinjun Li#. FBXO9 mediates the cancer-promoting effects of ZNF143 by degrading FBXW7 and facilitates drug resistance in hepatocellular carcinoma. Front. Oncol. 12: doi: 10.3389/fonc.2022.930220
Chen X, Wang Z, Zhao X, Zhang L, Zhou L, Li X, Ge C, Zhao F, Chen T, Xie H, Cui Y, Tian H, Li H, Yao M, Li J#. STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1. Oncogene. 41(17):2492-2504, 2022.
Xiaoxia Chen, Tianshu Chen, Lili Zhang, Zhenyu Wang, Qingqing Zhou, Tingting Huang, Chao Ge, Huili Xu, Miaoxin Zhu, Fangyu Zhao, Ming Yao, Hua Tian, Hong Li, Xiaoli Zhu#, Jinjun Li#. Cyclodextrin-Mediated Formation of Porous RNA Nanospheres and Their Application in Synergistic Targeted Therapeutics of Hepatocellular Carcinoma. Biomaterials 261:120304, 2020
Zhang L*, Huo Q*, Ge C, Zhao F, Zhou Q, Chen X, Tian H, Chen T, Xie H, Cui Y, Yao M, Li H#, Li J#. ZNF143-mediated H3K9 trimethylation upregulates CDC6 by activating MDIG in hepatocellular carcinoma. Cancer Res 80(12): 2599-611, 2020
Jing Yang*, Lili Zhang*, Zhiyuan Jiang, Chao Ge, Fangyu Zhao, Jingyi Jiang, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, Ming Yao, Hong Li, Jinjun Li#. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression. Theranostics 9(20): 5810-5827, 2019
Cong Chen, Chao Ge, Zheng Liu, Liangyu Li, Fangyu Zhao, Hua Tian, Taoyang Chen, Hong Li, Ming Yao, Jinjun Li#. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression. J Exp Clin Cancer Res 37(1):263, 2018
Jiang J*, Liu Z*, Ge C, Chen C, Zhao F, Li H, Chen T, Yao M, Li J#. NK3 Homeobox 1 (NKX3.1) Upregulates Forkhead Box O1 Expression in Hepatocellular Carcinoma and Thereby Suppresses Tumor Proliferation and Invasion. J Biol Chem 292(47) 19146–19159, 2017
Huo Q, Ge C, Tian H, Sun J, Cui M, Li H, Zhao F, Chen T, Xie H, Cui Y, Yao M, Li J#. Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity. Cell Death Dis. 8(5):e2766, 2017
Hua Tian, Chao Ge, Fangyu Zhao, Miaoxin Zhu, Lin Zhang, Qi Huo, Hong Li, Taoyang Chen, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li#. Downregulation of AZGP1 by Ikaros and histone deacetylase promotes metastasis through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma. Carcinogenesis 38 (2): 207-217, 2017
Zhang L, Ge C, Zhao F, Zhang Y, Wang X, Yao M, Li J#. NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling. Cancer Res 76(23): 7059-71, 2016
Hua Tian, Chao Ge, Hong Li, Fangyu Zhao, Helei Hou, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li#. Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma. Hepatology 59(4): 1459-1470, 2014
Helei Hou, Hefen Sun, Ping Lu, Chao Ge, Lixing Zhang, Hong Li, Fangyu Zhao, Hua Tian, Lin Zhang, Taoyang Chen, Ming Yao, Jinjun Li#. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse xenograft models of human hepatocellular carcinoma. Mol Cancer Therap 12(12): 2874-2884, 2013
Lixing Zhang, Hefen Sun, Fangyu Zhao, Ping Lu, Chao Ge, Hong Li, Helei Hou, Mingxia Yan, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Xiaowu Huang, Jia Fan, Ming Yao, Jinjun Li#. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocelluar carcinoma. Cancer Res 72(16): 4276-4285, 2012
Hong Li, Chao Ge, Fangyu Zhao, Mingxia Yan, Chen Hu, Deshui Jia, Hua Tian, Miaoxin Zhu,Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Jianren Gu, Hong Tu, Xianghuo He, Ming Yao, Yongzhong Liu, Jinjun Li#. HIF-1α-activated ANGPTL4 contributes to tumor metastasis via VCAM-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology 54(3): 910-919, 2011
Zheng Zhu*, Xiangfang Hao*, Mingxia Yan, Ming Yao, Chao Ge, Jianren Gu, Jinjun Li#. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126(9): 2067-2078, 2010
Chen Hu*, Hong Li*, Jin-Jun Li#, Zheng Zhu, Sheng-Yong Yin, Xiang-Fang Hao, Ming Yao, Shu-Sen Zheng, Jian-Ren Gu. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 29(12): 2289-2297, 2008.
Yin S*, Li J*, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S#, Gu J#. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120(7):1444-1450, 2007
